2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1605

Prevalence of Anterior Uveitis in Patients with Spondyloarthropathy in a Single US Academic Center: A Retrospective Study from Routine Care
Abstract Number: 1606

The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative
Abstract Number: 1607

Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Abstract Number: 1608

The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Abstract Number: 1609

The Incidence Rate of Spondyloarthritis in Slovenia
Abstract Number: 1610

Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Abstract Number: 1611

Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Abstract Number: 1612

Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database
Abstract Number: 1613

Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort
Abstract Number: 1614

Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
Abstract Number: 1615

Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Abstract Number: 1616

Region-Specific Differences in Clinical Presentation of Patients with Axial Spondyloarthritis – Results from a Large Multinational Cohort Study
Abstract Number: 1617

Influence of Disease Activity in the Physical Activity of Psoriatic Arthritis Patients
Abstract Number: 1618

Adipose Tissue Inflammation in Psoriatic Arthritis: Overexpression of a Wide Array of Inflammatory Mediators and Associations with Disease and Treatment Characteristics
Abstract Number: 1619

Patterns and Outcomes on As Patients Disease Activity Using Smart System of Disease Management (SSDM): Analysis of T2T Pattern Shift and the Correlation between Disease Activity and Mental Health

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].